Real-life acute lung function changes after lumacaftor/ivacaftor first administration in pediatric patients with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 16, Issue 6, 2017, Pages 709-712

  Labaste, Aurélie ^a   Ohlmann, Camille ^a   Mainguy, Catherine ^a   Jubin, Virginie ^a   Perceval, Marie ^a   Coutier, Laurianne ^a   Reix, Philippe ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b UMR5558   (France)

Author keywords

Acute; Airway obstruction; Bronchoconstriction; Cystic fibrosis; Lumacaftor; Modulators; Pediatric

Indexed keywords

BRONCHODILATING AGENT; IVACAFTOR; LUMACAFTOR; SALBUTAMOL; SHORT ACTING BRONCHODILATOR; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CHLORIDE CHANNEL STIMULATING AGENT; LUMACAFTOR, IVACAFTOR DRUG COMBINATION; QUINOLONE DERIVATIVE;

ADOLESCENT; AIRWAY OBSTRUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; OUTCOME ASSESSMENT; PATIENT RISK; PEDIATRICS; PHYSICAL EXAMINATION; RISK ASSESSMENT; RISK FACTOR; SPIROMETRY; WHEEZING; DRUG COMBINATION; DRUG EFFECT; DRUG MONITORING; FRANCE; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PROCEDURES; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

ADOLESCENT; AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; FORCED EXPIRATORY VOLUME; FRANCE; HUMANS; MALE; QUINOLONES; RESPIRATORY FUNCTION TESTS; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 85019365990     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2017.05.002     Document Type: Article

References (9)

1. Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M., et al. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373:3 (2015), 220–231.
2. Marigowda, G., Liu, F., Waltz, D., Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy. J Cyst Fibros, 2016.
3. Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R.O., Burgos, F., Casaburi, R., et al. Interpretative strategies for lung function tests. Eur Respir J 26:5 (2005), 948–968.
4. Stanojevic, S., Wade, A., Stocks, J., Hankinson, J., Coates, A.L., Pan, H., et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 177:3 (2008), 253–260.
5. Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Drevinek, P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:18 (2011), 1663–1672.
6. Michoud, M.C., Robert, R., Hassan, M., Moynihan, B., Haston, C., Govindaraju, V., et al. Role of the cystic fibrosis transmembrane conductance channel in human airway smooth muscle. Am J Respir Cell Mol Biol 40:2 (2009), 217–222.
7. Cook, D.P., Rector, M.V., Bouzek, D.C., Michalski, A.S., Gansemer, N.D., Reznikov, L.R., et al. Cystic fibrosis transmembrane conductance regulator in sarcoplasmic reticulum of airway smooth muscle. Implications for airway contractility. Am J Respir Crit Care Med 193:4 (2016), 417–426.
8. Adam, R.J., Hisert, K.B., Dodd, J.D., Grogan, B., Launspach, J.L., Barnes, J.K., et al. Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalities. JCI Insight, 1(4), 2016, e86183.
9. McCuaig, S., Martin, J.G., How the airway smooth muscle in cystic fibrosis reacts in proinflammatory conditions: implications for airway hyper-responsiveness and asthma in cystic fibrosis. Lancet Respir Med 1:2 (2013), 137–147.